Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Miravirsen in Null Responder HCV Genotype 1
NCT01727934Phase 2Unknown
- Sponsor
- Santaris Pharma
- Start
- Nov 2012
- Primary completion
- Jan 2014
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 1
01
Overview
A Phase 2 trial of miravirsen in hepatitis C (HCV), sponsored by Santaris Pharma. Status: unknown.
02
Drugs
miravirsen
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT01727934.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01727934.